Author's response to reviews

Title: Prevalence and Clinical Impact of Magnesium Disorders in End Stage Renal Disease: A Protocol for a Systematic Review

Authors:

John Floridis (john.floridis@nt.gov.au)
Asanga Abeyaratne (Asanga.Abeyaratne@nt.gov.au)
Sandawana W Majoni (William.Majoni@nt.gov.au)

Version: 2 Date: 15 January 2015

Author's response to reviews:

Title: Prevalence and Clinical Impact of Magnesium Disorders in End Stage Renal Disease: A Protocol for a Systematic Review

Authors: John Floridis, Asanga Abeyaratne, Sandawana William Majoni

Department of Nephrology
Royal Darwin Hospital, Rocklands Drive, Tiwi, Northern Territory, Australia 0810

Version: 2 Date: 15 January 2015

Magnesium disorders in people with end stage renal disease may be more common than is currently known. It is not clear in many guidelines whether treatment to correct magnesium disorders is warranted. The strength of this review is that it will clearly establish the prevalence of magnesium disorders in ESRD patients. Whilst previous literature has highlighted the concerns around magnesium disturbances in this population, results are variable with many associations in place, based on indirect in vitro and in vivo studies. Furthermore, whilst hypomagnesaemia has been acknowledged as a concern due to impact on clinical outcomes, there is still no consensus about how to manage this electrolyte imbalance in clinical practice - with or without magnesium supplementation in people with ESRD.

Corresponding Author:
John Floridis
john.floridis@nt.gov.au
p 08 8922 8888